(Reuters) -Zealand Pharma is halting development of a potential next-generation obesity drug after concluding the market has become too crowded for it to stand out, Bloomberg News reported on Thursday, citing an interview with the company CEO.
(Reporting by Mariam Sunny in Bengaluru; Editing by Vijay Kishore)
